MRK Merck & Co Inc

$-1.16 (-1.44%)

MRK Stock Analysis Overview

What this means: InvestorsObserver gives Merck & Co Inc (MRK) an overall rank of 40, which is below average. Merck & Co Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 40 means that 60% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full MRK report

Merck & Co Inc (MRK) Analyst Forecast

Next 12 months ➝Current Price$79.5652-week High$92.6452-week Low$65.25MEAN$93.40+17.40%HIGH$107.00+34.49%LOW$88.00+10.61%
  • Last Price$79.56
  • Previous Close$80.72
  • Change $-1.16
  • Open$80.18
  • Volume5,977,936
  • Avg. Volume (100-day)12,827,937
  • Market Capitalization$201B
  • Days Range $79.13 - $80.46
  • 52-week Range $65.25 - $92.64
  • Dividend Yield3.02%
  • Ex. Dividend Date06/12/2020
  • P-E20.4
  • EPS3.95
  • Earnings Date08/04/2020
  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • Avg. Analyst Rec.
  • Beta0.358
  • PEG Ratio2.15
  • Volatility0.25
  • Average True Range0.04
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.